Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Focusing on the unmet medical needs of patients with rare disorders and their families

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

01.06

Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

01.04

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

12.06

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

11.22

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™